Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and Non-European adults with attention-deficit/ hyperactivity disorder

European Journal of Psychiatry

Volumn 27, Issue 3, 2013, Pages 206-224

  Camporeale, Angelo ^a   Upadhyaya, Himanshu ^a   Ramos Quiroga, J Antoni ^b,c   Williams, David ^d   Tanaka, Yoko ^a   Lane, Jeannine R ^d   Escobar, Rodrigo ^a   Trzepacz, Paula ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d SYNEOS HEALTH   (United States)

Author keywords

Adult; Atomoxetine; Attention deficit hyperactivity disorder; European

Indexed keywords

ATOMOXETINE; PLACEBO;

ADULT; ALCOHOL ABUSE; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; BODY MASS; BODY WEIGHT; BRADYKINESIA; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84885770893     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: 10.4321/S0213-61632013000300005     Document Type: Article

References (40)

1. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46(9): 1234-1242.
2. Faraone SV, Biederman J. Neurobiology of attentiondeficit hyperactivity disorder. Biol Psychiatry 1998; 44(10): 951-958.
3. Zametkin AJ, Liotta W. The neurobiology of attentiondeficit/hyperactivity disorder. J Clin Psychiatry 1998; 59(Suppl 7): 17-23.
4. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111(2): 279-289.
5. Mannuzza S, Klein RG, Moulton JL 3rd. Persistence of attention-deficit/hyperactivity disorder into adulthood: what have we learned from the prospective follow-up studies? J Atten Disord 2003; 7(2): 93-100.
6. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27(2): 187-201.
7. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry 2010; 10:67.
8. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009; 29(1): 44-50.
9. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system methylphenidate in adults with attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 2010; 30(5): 549-553.
10. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53(2): 112-120.
11. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155(5): 693-695.
12. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2005; 57(5): 456-463.
13. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 2003; 48(8): 546-554.
14. Kooij JJ, Burger H, Boonstra AM, Van der Linden PD, Kalma LE, Buitelaar JK. Efficacy and safety of methylphenidate in 45 adults with attentiondeficit/hyperactivity disorder. A randomized placebo-controlled double-blind crossover trial. Psychol Med 2004; 34(6): 973-982.
15. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemelä A, Trott GE, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63(10): 981-989.
16. Himpel S, Banaschewski T, Heise CA, Rothenberger A. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert Opin Drug Saf 2005; 4(2): 311-321.
17. Vaughan B, Fegert J, Kratochvil CJ. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2009; 10(4): 669-676.
18. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114(1): e1-e8.
19. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83.
20. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159(11): 1896-901.
21. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004; 43(7): 896-904.
22. Newcorn JH, Michelson D, Kratochvil CJ, Allen AJ, Ruff DD, Moore RJ. Atomoxetine Low-dose Study Group. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006; 118(6): e1701-e1706.
23. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, et al. Results from 2 proofof-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63(12): 1140-1147.
24. Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96(1-2): 145-154.
25. Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26(3): 212-221.
26. Upadhyaya H, Ramos-Quiroga JA, Adler JA, Williams D, Tanaka Y, Lane JR, et al. Maintenance of Response after Open-Label Treatment with Atomoxetine Hydrochloride in International European and Non-European Adult Outpatients with Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled, Randomised Withdrawal Study. Eur. J Psychiat. Submitted 2012.
27. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda: MultiHealth Systems, Inc.; 1999.
28. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education, and Welfare; 1976.
29. Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Clin Ther 2012; 34(2): 363-373.
30. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007; 164(7): 1035-1043.
31. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50-55.
32. Riskind JH, Beck AT, Brown G, Steer RA. Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis 1987; 175(8): 474-479.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
34. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4): 278-296.
35. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010; 33(10): 821-842.
36. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64(2):205-222.
37. Strattera (atomoxetine hydrochloride) [package insert]. Indianapolis: Eli Lilly and Company; 2011.
38. Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007; 17(5): 689-700.
39. Impey M, Heun R. Completed suicide, ideation and attempt in attention deficit hyperactivity disorder. Acta Psychiatr Scand 2012; 125(2): 93-102.
40. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008; 47(2): 209-218.